OLD Second National Bank of Aurora Has $6.82 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

OLD Second National Bank of Aurora cut its holdings in Eli Lilly and Company (NYSE:LLY) by 5.8% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 8,763 shares of the company’s stock after selling 544 shares during the quarter. Eli Lilly and Company comprises approximately 1.8% of OLD Second National Bank of Aurora’s portfolio, making the stock its 13th largest holding. OLD Second National Bank of Aurora’s holdings in Eli Lilly and Company were worth $6,817,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Lipe & Dalton bought a new position in Eli Lilly and Company in the fourth quarter valued at about $26,000. Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the last quarter. Activest Wealth Management bought a new position in Eli Lilly and Company in the first quarter valued at about $39,000. Tidemark LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at about $29,000. Finally, Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company in the first quarter valued at about $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Morgan Stanley reiterated an “overweight” rating and issued a $1,023.00 target price on shares of Eli Lilly and Company in a report on Friday, July 5th. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Truist Financial reiterated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a report on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $843.00.

Eli Lilly and Company Stock Up 1.6 %

Eli Lilly and Company stock traded up $14.85 during mid-day trading on Friday, reaching $948.99. The company’s stock had a trading volume of 1,272,568 shares, compared to its average volume of 2,923,477. The company has a market capitalization of $901.93 billion, a price-to-earnings ratio of 139.25, a price-to-earnings-growth ratio of 2.05 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $949.88. The business’s 50 day simple moving average is $845.17 and its 200 day simple moving average is $760.02. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter last year, the firm posted $1.62 EPS. The company’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.55%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,214,704 shares of company stock valued at $1,066,841,316. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.